

PHARMACY POLICY STATEMENT

Georgia Medicaid

DRUG NAME	Fasenra (benralizumab)
BILLING CODE	J0517
BENEFIT TYPE	Medical
SITE OF SERVICE ALLOWED	Home/Office/Outpatient Hospital
COVERAGE REQUIREMENTS	Prior Authorization Required (Non-Preferred Product) QUANTITY LIMIT – 1 syringe or 1 pen/month
LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY	Click Here

Fasenra (benralizumab) is a non-preferred product and will only be considered for coverage under the medical benefit when the following criteria are met:

Members must be clinically diagnosed with one of the following disease states and meet their individual criteria as stated.

SEVERE ASTHMA

For initial authorization:

1. Member must be 12 years of age or older; AND
2. Medication must be prescribed by or in consultation with a pulmonologist, immunologist or allergist; AND
3. Member has a blood eosinophil count of at least 300 cells/ μ L or at least 150 cells/ μ L if taking maintenance oral corticosteroids (OCS); AND
4. Member has at least two documented severe asthma exacerbations requiring oral corticosteroids (OCS), or at least one requiring hospitalization, within last year; AND
5. Member's asthma has been inadequately controlled after 3 month of conventional treatment of medium to high doses of inhaled corticosteroids (ICS) and long acting beta 2-agonists (LABA); AND
6. Medication is being used as add-on maintenance treatment to conventional therapies for asthma (i.e., ICS, LABA, etc.); AND
7. Medication is not used in conjunction with any other biologic therapy for asthma.
8. Dosage allowed: 30 mg every 4 weeks for the first 3 doses, followed by once every 8 weeks thereafter.

If member meets all the requirements listed above, the medication will be approved for 16 weeks.

For reauthorization:

1. Medication not being used as monotherapy for asthma; AND
2. Member must be in compliance with all other initial criteria; AND
3. Chart notes have been provided that show the member has demonstrated improvement during 16 weeks of medication therapy:
 - a) Decreased frequency of emergency department visits or hospitalizations due to asthma exacerbations; OR
 - b) Increase in percent predicted FEV1 from pretreatment baseline; OR
 - c) Improved functional ability (i.e. decreased effect of asthma on ability to exercise, function in school or at work, or quality of sleep); OR
 - d) Decreased utilization of rescue medications or oral corticosteroids.

If member meets all the reauthorization requirements above, the medication will be approved for an additional 12 months.

CareSource considers Fasentra (benralizumab) not medically necessary for the treatment of the diseases that are not listed in this document.

DATE	ACTION/DESCRIPTION
12/01/2017	New policy for Fasentra created.
05/12/2018	Baseline (pre-benralizumab treatment) peripheral blood eosinophil level was changed from 300 to ≥ 150 cells/ μ L within the past 6 weeks.
11/25/2020	Eosinophil count was updated to be consistent with guidelines; exacerbation number was updated to be consistent with guidelines (2 requiring OCS or 1 requiring hospitalization in the last year); changed from not to be used with Nucala or Cinqair to not to be used with any other asthma biologic.

References:

1. Fasentra [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; October 2019.
2. ClinicalTrials.gov web site. U.S. National Library of Medicine. Identifier NCT01914757 Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β 2 Agonist. Available at: <https://clinicaltrials.gov/ct2/show/NCT01914757?term=benralizumab&recrs=e&draw=1&rank=6>.
3. Walford HH, Doherty TA. Diagnosis and management of eosinophilic asthma: a US perspective. *J Asthma Allergy*. 2014;7:53–65.
4. ClinicalTrials.gov web site. U.S. National Library of Medicine. Identifier NCT02075255. Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy. Available at: <https://clinicaltrials.gov/ct2/show/NCT02075255?term=benralizumab&recrs=e&draw=1&rank=7>.
5. Goldman M, Hirsch I, Zangrilli JG, et al. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies. *Curr Med Res Opin*. 2017 Sep;33(9):1605-1613.
6. Difficult-To-Treat & Severe Asthma in Adolescent and Adult Patients: Diagnosis and Management. Global Initiative For Asthma (GINA); Apr. 2019. Available at: <https://ginasthma.org/wp-content/uploads/2018/11/GINA-SA-FINAL-wms.pdf>.
7. Kostikas K, Brindicci C, Patalano F. Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD. *Curr Drug Targets*. 2018;19(16):1882-1896. doi:10.2174/1389450119666180212120012
8. 2020 Focused Updates To The Asthma Management Guidelines. National Institute of Health; Dec 2020. Available at: <https://www.nhlbi.nih.gov/health-topics/asthma-management-guidelines-2020-updates>.

Effective date: 07/01/2021

Revised date: 11/25/2020